Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A445 plus tislelizumab in advanced solid tumors (UC, RCC, melanoma)
CTR20223270Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gimistotug, tislelizumab in transitional cell carcinoma (TCC), clear cell renal cell carcinoma (ccRCC), melanoma, sponsored by BeiGene. Started Dec 2022; status: terminated.
02
Drugs
gimistotugtislelizumab
03
Conditions
transitional cell carcinoma (TCC)clear cell renal cell carcinoma (ccRCC)melanoma
Beyond the preview
Go deeper on CTR20223270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223270.